Horgan Denis, Baird Anne-Marie, Middleton Mark, Mihaylova Zhasmina, Van Meerbeeck Jan P, Vogel-Claussen Jens, Van Schil Paul E, Malvehy Josep, Ascierto Paolo Antonio, Dube France, Zaiac Michael, Lal Jonathan A, Kamińska-Winciorek Grażyna, Donia Marco, André Thierry, Kozaric Marta, Osterlund Pia, Dumitrascu Dan Lucian, Bertolaccini Luca
European Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.
Healthcare (Basel). 2022 Aug 25;10(9):1618. doi: 10.3390/healthcare10091618.
Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices-such as population-level screening for lung cancer-are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.
癌症是欧盟国家第二大死因,应对癌症的需求显而易见。新的科学认识、技术和方法为显著改善诊断和治疗开辟了前景。然而,应用情况并不均衡,研究需求和潜力超过了目前可用的资源,明显有益的做法——如针对肺癌的人群筛查——仍未普及,患者和幸存者的生活质量才刚刚开始得到应有的关注。本文主要基于欧洲个性化医疗联盟(EAPM)组织的一系列多利益相关方专家研讨会,着眼于其中一些具体情况,以规划前进的方向。这项工作的一部分还涉及考虑欧洲及其成员国的特殊性,在这些地方,由于各国和各地区在癌症治疗方法、当地流行病学以及卫生系统方面存在巨大差异,规划前进方向的复杂性成倍增加。尽管癌症以及各国和各地区的资源与癌症治疗方法存在种种差异,但为所有欧洲公民提供更广泛、更平等的最佳可用治疗的共同目标是一致的。